Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (888)	2/29/2008 4:15:02 PM
From: tuck	Read Replies (1) \| Respond to of 933

>>Actually, I was serious. With composition of matter (from your notes of the CC), I should have said "relative" weakness. So company "F" (for "Formulation King) would have three shots on goal, instead of one (or two/two, etc.).<< Perhaps, but that seems unlikely to me, as I don't think there's much differentiation in the underlying compounds, particularly if it is Conforma/Biogen that is "F". >>Anyway, a few more grunts and you'll be up 10% in a couple of days.<< I settled for my one grunt and 6% in one day, which seems to have been a good move, so far. My Mom, OTOH, has been a long term holder at 3 bucks and change, so I'm certainly pulling for Tanespimycin to make it. Cheers, Tuck